We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current CYCC market cap is 7.79M. The company's latest EPS is USD -0.5034 and P/E is -0.68.
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 31k | 29k | 4k | 10k | 0 |
| Operating Income | -5.36M | -4.36M | -3.64M | -2.18M | -1.83M |
| Net Income | -5.32M | -2.95M | -3.26M | -1.96M | -3.05M |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 0 | 0 | 0 | 420k | 43k |
| Operating Income | -10.64M | -22.94M | -27.66M | -25.45M | -12M |
| Net Income | -12.42M | -19.09M | -21.4M | -22.76M | -11.21M |
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 8.81M | 6.17M | 8.19M | 5.38M | 4.09M |
| Total Liabilities | 8.2M | 8.37M | 7.19M | 6.35M | 6.27M |
| Total Equity | 607k | -2.21M | 999k | -970k | -2.17M |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 36.8M | 42.59M | 27.5M | 8.81M | 4.09M |
| Total Liabilities | 3.54M | 5.32M | 7.5M | 8.2M | 6.27M |
| Total Equity | 33.26M | 37.26M | 15.51M | 607k | -2.17M |
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -16.11M | -483k | -3.57M | -6.63M | -7.99M |
| Investing | -6k | N/A | N/A | N/A | N/A |
| Financing | 848k | -79k | 6.21M | 6.21M | 7.82M |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -7.93M | -18.54M | -20.83M | -16.11M | -7.99M |
| Investing | -96k | -27k | -7k | -6k | N/A |
| Financing | 29.5M | 21.74M | 3M | 848k | 7.82M |
| Market Cap | 7.79M |
| Price to Earnings Ratio | -0.68 |
| Price to Sales Ratio | 178.95 |
| Price to Cash Ratio | 2.41 |
| Price to Book Ratio | -3.48 |
| Dividend Yield | - |
| Shares Outstanding | 22.27M |
| Average Volume (1 week) | 7.13M |
| Average Volume (1 Month) | 3.93M |
| 52 Week Change | -98.57% |
| 52 Week High | 39.84 |
| 52 Week Low | 0.25 |
| Spread (Intraday) | 0.02 (5.69%) |
| Company Name | Cyclacel Pharmaceuticals Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.cyclacel.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
